// App-Quantinova.ai

THU0354 (2018) : Impact of biologic therapy in sjogren’s syndromepatients with overlapping autoimmune diseases or extraglandular manifestations. a systematic review of literature

Researchers

Presenter

  • G.E. Fragoulis

Principal Investigators

  • E. Nikiphorou

  • A. Alunno

  • F. Ng

  • A.G. Tzioufas

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Academic Rheumatology, King's College London

  • Rheumatology Unit, University of Verona, Verona, Italy

  • Institute of Cellular Medicine, University of Newcastle, Newcastle, UK

  • Pathophysiology, National University of Athens, Athens, Greece

Locations

  • United Kingdom

  • Italy

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • Certolizumab pegol

  • Tocilizumab

  • secukinumab

  • Ustekinumab

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • Abatacept

  • Belimumab

  • golimumab

  • Rituximab

  • Anakinra

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved